title: Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate.
abstract: Structural characterization was performed on an antibody-drug conjugate (ADC), composed of an IgG1 monoclonal antibody (mAb), mertansine drug (DM1), and a noncleavable linker. The DM1 molecules were conjugated through nonspecific modification of the mAb at solvent-exposed lysine residues. Due to the nature of the lysine conjugation process, the ADC molecules are heterogeneous, containing a range of species that differ with respect to the number of DM1 per antibody molecule. The DM1 distribution profile of the ADC was characterized by electrospray ionization mass spectrometry (ESI-MS) and capillary isoelectric focusing (cIEF), which showed that 0-8 DM1s were conjugated to an antibody molecule. By taking advantage of the high-quality MS/MS spectra and the accurate mass detection of diagnostic DM1 fragment ions generated from the higher-energy collisional dissociation (HCD) approach, we were able to identify 76 conjugation sites in the ADC, which covered approximately 83% of all the putative conjugation sites. The diagnostic DM1 fragment ions discovered in this study can be readily used for the characterization of other ADCs with maytansinoid derivatives as payload. Differential scanning calorimetric (DSC) analysis of the ADC indicated that the conjugation of DM1 destabilized the C(H)2 domain of the molecule, which is likely due to conjugation of DM1 on lysine residues in the C(H)2 domain. As a result, methionine at position 258 of the heavy chain, which is located in the C(H)2 domain of the antibody, is more susceptible to oxidation in thermally stressed ADC samples when compared to that of the naked antibody.
authors.affiliation: Department of Process Development, Amgen Inc. , Thousand Oaks, California 91320, United States.
authors.forename: Quanzhou
authors.initials: Q
authors.lastname: Luo
authors.affiliation: Department of Process Development, Amgen Inc. , Thousand Oaks, California 91320, United States.
authors.forename: Hyo Helen
authors.initials: HH
authors.lastname: Chung
authors.affiliation: Department of Process Development, Amgen Inc. , Thousand Oaks, California 91320, United States.
authors.forename: Christopher
authors.initials: C
authors.lastname: Borths
authors.affiliation: Department of Process Development, Amgen Inc. , Thousand Oaks, California 91320, United States.
authors.forename: Matthew
authors.initials: M
authors.lastname: Janson
authors.affiliation: Department of Process Development, Amgen Inc. , Thousand Oaks, California 91320, United States.
authors.forename: Jie
authors.initials: J
authors.lastname: Wen
authors.affiliation: Department of Process Development, Amgen Inc. , Thousand Oaks, California 91320, United States.
authors.forename: Marisa K
authors.initials: MK
authors.lastname: Joubert
authors.affiliation: Department of Process Development, Amgen Inc. , Thousand Oaks, California 91320, United States.
authors.forename: Jette
authors.initials: J
authors.lastname: Wypych
mesh_terms: D000911:Antibodies, Monoclonal / Q000737:chemistry*; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry*; D008453:Maytansine / Q000737:chemistry*; D008958:Models, Molecular; D008968:Molecular Conformation; D053719:Tandem Mass Spectrometry
chemical_list: D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D008453:Maytansine